Add-on perampanel in Lance–Adams syndrome

Perampanel (PER) is the first-in-class selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist that has been licensed and marketed as antiepileptic drug (AED) indicated for patients with partial-onset and primary generalized tonic–clonic seizures. A...

Descripción completa

Detalles Bibliográficos
Autores principales: Steinhoff, Bernhard J., Bacher, Matthias, Kurth, Christoph, Staack, Anke M., Kornmeier, Reinhold
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4939387/
https://www.ncbi.nlm.nih.gov/pubmed/27437182
http://dx.doi.org/10.1016/j.ebcr.2016.05.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4939387/
https://www.ncbi.nlm.nih.gov/pubmed/27437182
http://dx.doi.org/10.1016/j.ebcr.2016.05.001

Ejemplares similares